GILD

GILEAD SCIENCES INC

71.6800
USD
-0.91%
71.6800
USD
-0.91%
64.2700 89.5400
52 weeks
52 weeks

Mkt Cap 92.91B

Shares Out 1.30B

new Chat
Send me real-time posts from this site at my email

Gilead was Great Once but is Now Awful and Depressing

How bad is Gilead Sciences (GILD) these days? So bad that analysts, scrambling for something encouraging to say after another quarter of disappointing earnings, praised the company for not cutting sales guidance again.

Gilead is a great biotech company. Its drugs helped transform HIV from a fatal epidemic into a chronic, manageable and survivable disease. For an encore, Gilead cured hepatitis C for almost every patient that can swallow a daily pill for three months. Patients benefited. Shareholders profited.

But greatness doesn't last forever. Gilead is experiencing a stretch of awfulness right now that I can only describe as depressing. The company's current performance almost physically hurts.

Third quarter earnings reported Tuesday night was a retread of the same...


More